Journal
CANCER CELL
Volume 30, Issue 4, Pages 515-517Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2016.09.016
Keywords
-
Categories
Ask authors/readers for more resources
In two recent studies, the HIF2 alpha antagonist, PT2399, decreased HIF2 alpha-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2 alpha as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2 alpha antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
